US
US health industry outlines cost saving plans
June 3, 2009Sales and Marketing US, US healthcare, healthcare, industry
The US healthcare industry has said how it contribute to President Obama’s drive to cut healthcare costs, and help save …
Companies poised for swine flu vaccine drive
May 29, 2009Research and Development, Sales and Marketing US, h1n1, vaccines
Pharmaceutical manufacturers now have access to the swine flu seed virus that can be used to start full-blown production of …
Ranbaxy woes continue with antibiotic recall
May 6, 2009Sales and Marketing Ranbaxy, US
Indian drugmaker Ranbaxy Laboratories has recalled an antibiotic on sale in the US, suggesting that it still has some way …
Coast first casualty in US overhaul of IRB system
May 5, 2009Research and Development FDA, US
A US company offering institutional review board services to sponsors of clinical trials has been forced to close its doors …
Committee approves limited use of Seroquel in depression
April 9, 2009Research and Development, Sales and Marketing AZ, Seroquel, US
An FDA advisory committee has concluded that safety concerns mean that Seroquel XR should not be used to treat anxiety, …
US prescription growth stalls in 2008
April 3, 2009Sales and Marketing US
US prescription sales growth was just 1.3% in 2008, well down on the typical 5%-plus in recent years, according to …
Biosimilars: time for an approval pathway in the US
March 23, 2009Research and Development, Sales and Marketing US, generics
Congress has received another bill seeking to establish a biosimilars approval pathway in the US. HR 1427 represents the latest …
Sanofi boosted by Multaq vote of approval
March 19, 2009Research and Development, Sales and Marketing FDA, Multaq, Sanofi, US
An FDA committee has recommended Sanofi-Aventis' new atrial fibrillation treatment Multaq, the company's most important late-stage drug. The FDA cardiovascular …
Biosimilars bill offers 12 years’ marketing exclusivity
March 19, 2009Research and Development US, generics
The US moved one step closer to creating a market for biosimilars – substitutable versions of branded biologic drugs – …
Obama ends stem cell funding ban
March 10, 2009Research and Development US, stem cell
President Obama has lifted the US ban on federal funding for new stem cell research, signalling another marked departure in …
Obama makes ‘downpayment’ on US healthcare reform
March 5, 2009Research and Development US, healthcare
President Barack Obama has reiterated his aim of bringing universal healthcare to the US and has put a $76.8 billion …
R&D tax credits among anticipated changes for US healthcare
February 24, 2009Research and Development US, healthcare
With the election of Barack Obama, widespread changes are anticipated for US healthcare and ultimately for the pharmaceutical industry. Although …
FDA finalises transgenic animals guide
January 23, 2009Research and Development, Sales and Marketing FDA, US, reg
The route map for companies wishing to sell medicines made in genetically-engineered animals has been drawn up by the FDA. …
Declaring doctor payments
December 16, 2008Research and Development, Sales and Marketing ABPI, EFPIA, Europe, UK, US, ethics, industry relations, payments
A number of pharmaceutical companies in the US have recently announced they will declare all the payments to healthcare professionals. …
Latest content
FibroFind appoints Lee Borthwick as CEO
